



Where Knowledge is Created and Shared

Yale Pathology

Pathology Grand Rounds Thursday, April 7th 12:30-1:30pm

Hosted by: Manju Prasad, MD



Mina L. Xu, MD

Associate Professor of Pathology and Laboratory Medicine, Director of Hematopathology, Department of Pathology, Yale School of Medicine

Discovering a Monoblast Marker

Needs: This course addresses the need to understand how to increase reliability in the diagnosis and follow-up of monocytic leukemias. The specific clinical gap to be addressed by pathologists has been demonstrated in a recent multicenter study “concordance among hematopathologists in classifying blasts plus promonocytes: a bone marrow pathology study.” Recent studies in the biology of our newly discovered biomarker raises the possibility that it may be involved in tumor susceptibility to new therapies.

Objectives: Understand the diagnostic and clinical dilemma surrounding myeloid neoplasms with monocytic differentiation; Appreciate the advantages and limitations of a new biomarker to be used on core bone marrow biopsies and soft tissue samples; Learn about the biology of IRF8 in the context of hematopoietic neoplasms.

[ZOOM LOGIN](#)



Continuing Medical Education
Yale CME

There is No Corporate Support for These Activities. Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Designation Statement: The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Target Audience: Multiple Specialties, Pathology. Financial Disclosures: Mina L. Xu, MD, Speaker to this educational activity, is Consultant and Advisory Board member of Seattle Genetics; Consultant to Blueprint Medicines; and Consultant to Pure Marrow. All the relevant financial relationships listed for this individual have been mitigated. None of the faculty/planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs. This course will fulfill the licensure requirement set forth by the State of Connecticut.